World Health Organization Corporate news releases, statements, and notes for media issued by the World Health Organization.
WHO: access to HIV medicines severely impacted by COVID-19 as AIDS response stalls
on 06/07/2020 at 4:42 pm
Seventy-three countries have warned that they are at risk of stock-outs of antiretroviral (ARV) medicines as a result of the COVID-19 pandemic, according to a new WHO survey conducted ahead of the International AIDS Society’s biannual conference. Twenty-four countries reported having either a critically low stock of ARVs or disruptions in the supply of these life-saving medicines. The survey follows a modelling exercise convened by WHO and UNAIDS in May which forecasted that a six-month disruption in access to ARVs could lead to a doubling in AIDS-related deaths in sub-Saharan Africa in 2020 alone. In 2019, an estimated 8.3 million people were benefiting from ARVs in the 24 countries now experiencing supply shortages. This represents about one third (33%) of all people taking HIV treatment globally. While there is no cure for HIV, ARVs can control the virus and prevent onward sexual transmission to other people.A failure of suppliers to deliver ARVs on time and a shut-down of land and air transport services, coupled with limited access to health services within countries as a result of the pandemic, were among the causes cited for the disruptions in the survey.The findings of this survey are deeply concerning,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Countries and their development partners must do all they can to ensure that people who need HIV treatment continue to access it. We cannot let the COVID-19 pandemic undo the hard-won gains in the global response to this disease. Stalled progressAccording to data released today from UNAIDS and WHO, new HIV infections fell by 39% between 2000 and 2019. HIV-related deaths fell by 51% over the same time period, and some 15 million lives were saved through the use of antiretroviral therapy. However, progresstowards global targets is stalling. Over the last two years, the annual number of new HIV infections has plateaued at 1.7 million and there was only a modest reduction in HIV-related death, from 730 000 in 2018 to 690 000 in 2019. Despite steady advances in scaling up treatment coverage – with more than 25 million people in need of ARVs receiving them in 2019 – key 2020 global targets will be missed. HIV prevention and testing services are not reaching the groups that need them most. Improved targeting of proven prevention and testing services will be critical to reinvigorate the global response to HIV. WHO guidance and country actionCOVID-19 risks exacerbating the situation. WHO recently developed guidance for countries on how to safely maintain access to essential health services during the pandemic, including for all people living with or affected by HIV. The guidance encourages countries to limit disruptions in access to HIV treatment through “multi-month dispensing,” a policy whereby medicines are prescribed for longer periods of time – up to six months. To date, 129 countries have adopted this policy. Countries are also mitigating the impact of the disruptions by working to maintain flights and supply chains, engaging communities in the delivery of HIV medicines, and working with manufacturers to overcome logistics challenges.New opportunities to treat HIV in young childrenAt the IAS conference, WHO will highlight how global progress in reducing HIV-related deaths can be accelerated by stepping up support and services for populations disproportionately impacted by the epidemic, including young children. In 2019, there were an estimated 95 000 HIV-related deaths and 150 000 new infections among children. Only about half (53%) of children in need of antiretroviral therapy were receiving it. A lack of optimal medicines with suitable pediatric formulations has been a longstanding barrier to improving health outcomes for children living with HIV.Last month, WHO welcomed a decision by the U.S. Food and Drug Administration to approve a new 5mg formulation of dolutegravir (DTG) for infants and children older than 4 weeks and weighing more than 3 kg. This decision will ensure that all children have rapid access to an optimal drug that, to date, has only been available for adults, adolescents and older children. WHO is committed to fast-tracking the prequalification of DTG as a generic drug so that it can be used as soon as possible by countries to save lives. Through a collaboration of multiple partners, we are likely to see generic versions of dolutegravir for children by early 2021, allowing for a rapid reduction in the cost of this medicine,” said Dr Meg Doherty, Director of the Department of Global HIV, Hepatitis and STI Programmes at WHO. “This will give us another new tool to reach children living with HIV and keep them alive and healthy.”Tackling opportunistic infectionsMany HIV-related deaths result from infections that take advantage of an individual’s weakened immune system. These include bacterial infections, such as tuberculosis, viral infections like hepatitis and COVID-19, parasitic infections such as toxoplasmosis and fungal infections, including histoplasmosis.Today, WHO is releasing new guidelines for the diagnosis and management of histoplasmosis, among people living with HIV. Histoplasmosis is highly prevalent in the WHO Region of the Americas, where as many as 15 600 new cases and 4500 deaths are reported each year among people living with HIV. Many of these deaths could be prevented through timely diagnosis and treatment of the disease.In recent years, the development of highly sensitive diagnostic tests has allowed for a rapid and accurate confirmation of histoplasmosis and earlier initiation of treatment. However, innovative diagnostics and optimal treatments for this disease are not yet widely available in resource-limited settings.
WHO launches iSupport Lite
on 06/07/2020 at 1:48 pm
The recent COVID-19 pandemic and resulting breakdown of community-based services for people with dementia and their caregivers emphasized the importance of providing caregivers with accessible public health messages to reduce caregiver stress and improve their mental health and well-being.WHO’s iSupport Lite consists of a set of practical support messages for caregivers of people with dementia extracted from iSupport, WHO’s knowledge and skills training programme.iSupport Lite offers tips for caregivers of people with dementia that can be drawn upon when and as needed. For caregivers who have already completed the comprehensive iSupport programme, iSupport Lite will act as a refresher, reinforcing previously-acquired caregiving skills and knowledge. iSupport Lite is available as posters on the WHO website and through social media.
WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19
on 04/07/2020 at 3:56 pm
WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients.The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation. These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect. For each of the drugs, the interim results do not provide solid evidence of increased mortality. There were, however, some associated safety signals in the clinical laboratory findings of the add-on Discovery trial, a participant in the Solidarity trial. These will also be reported in the peer-reviewed publication. This decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19. The interim Solidarity results are now being readied for peer-reviewed publication.
Statement of the twenty-fifth polio IHR Emergency Committee
on 03/07/2020 at 10:25 am
The twenty-fifth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened and opened by the Director General on 23 June 2020 with committee members attending via teleconference, supported by the WHO Secretariat. Dr Tedros in his opening remarks said that while there has been amazing progress on wild poliovirus in Africa, there is still much more work to do to end transmission in Pakistan and Afghanistan. Similarly, the significantly greater than expected number of circulating vaccine derived polio virus type-2 (cVDPV2) outbreaks are another major challenge. The COVID-19 pandemic has had a significant impact on public health programs, including polio eradication. As a result, the risk of the international spread of polio is likely to have increased considerably. At the same time, the polio infrastructure that has been developped in Pakistan and Afghanistan has been used to assist with the tracking and tracing as part of the COVID-19 pandemic response.He also remarked that the novel oral polio vaccine type-2, which will be made available under the Emergency Use Listing procedure (EUL), is expected to be an important new tool to stop the vicious cycle of using monovalent Sabin OPV2 to combat outbreaks, but in turn seeding new outbreaks of cVDPV2. Dr Tedros thanked the committee for their commitment and said he looked forward to receiving their advice.The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV). The WHO Secretariat presented a report of progress for affected IHR States Parties subject to Temporary Recommendations. The following IHR States Parties provided an update at the teleconference on the current situation and the implementation of the WHO Temporary Recommendations since the Committee last met on 26 March 2020: Afghanistan, Burkina Faso, Mali and Pakistan. In order to ease the burden on affected State Parties in the exceptional situation following the determination of the COVID-19 outbreak as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020, the following invited State Parties were asked to present their reports electronically only instead of attending via teleconference: Chad, Cote d’Ivoire, Ethiopia, Ghana, Malaysia, Niger, Nigeria, Philippines, Philippines, and Togo. All these States Parties have previously attended teleconferences of the committee to present their statements. Wild poliovirusThe global situation remains of great concern with the increased number of WPV1 cases that started in 2019 continuing in 2020. This year there have been 70 WPV1 cases as at 16 June 2020, compared to 57 for the same period in 2019, with no significant success yet in reversing this upward trend.In Pakistan transmission continues to be widespread, as indicated by both acute flaccid paralysis (AFP) surveillance and environmental sampling. WPV1 transmission continues to be widespread, with southern Khyber Pakhtunkhwa becoming a new WPV1 reservoir, and some areas such as Karachi and the Quetta block having uninterrupted transmission. There has also been expansion of WPV1 to previously polio free areas in Sindh and Punjab. In Afghanistan, the security situation remains very challenging. Inaccessibility and missed children particularly in the Southern Region have led to a large cohort of susceptible children in this part of Afghanistan. The risk of a major upsurge of cases is growing, with other parts of the country that have been free of WPV1 for some time now at risk of outbreaks. The number of provinces reporting WPV1 has increased from three in 2019 to 11 in 2020. This would again increase the risk of international spread. The Committee noted that based on results from sequencing of WPV1, there were recent instances of international spread of viruses from Pakistan to Afghanistan and from Afghanistan to Pakistan. The ongoing frequency of WPV1 international spread between the two countries and the increased vulnerability in other countries where routine immunization and polio prevention activities have both been adversely affected by the COVID-19 pandemic are two major factors that suggest the risk of international spread may be at the highest level since 2014. While border closures and lockdowns may mitigate the risk in the short term while in force, this would be outweighed in the longer term by falling population immunity through disruption of vaccination and the resumption of normal population movements.The Committee noted that at its meeting 15 – 17 June, the African Regional Certification Commission had accepted the evidence presented by Nigeria that it was now free of WPV1 infection, and commended this achievement by the Government of Nigeria and its partners.Vaccine derived poliovirus (VDPV)The multiple cirulating VDPV (cVDPV) outbreaks in four WHO regions (African, Eastern Mediterranean, South-east Asian and Western Pacific Regions) are very concerning, with one new country reporting an outbreak since the last meeting (Mali). Unlike historical experience, international spread of cVDPV2 has become quite common, with recent spread from Chad and Central African Republic to Cameroon; Nigeria, Togo and Ghana to Cote d’Ivoire; Nigeria to Benin, Ghana to Burkina Faso, Nigeria to Mali, Togo to Niger, Ghana and Benin to Togo, Angola to DR Congo, and Pakistan to Afghanistan. In addition, a new local emergence attributable to mOPV2 use has recently occurred in Ethiopia.In 2020, West Africa and Ethiopia are experiencing high levels of transmission of cVDPV2, and due to the pandemic, outbreak response has been significantly hampered, with many areas that have reported cases recently not having had an immunization response. The Committee repeated its strong support for the development and proposed Emergency Use Listing of the novel OPV2 vaccine which should become available mid-2020, and which it is hoped will result in no or very little seeding of further outbreaks. Impact of COVID-19The Committee noted that in many polio infected countries, the COVID-19 pandemic has disrupted polio surveillance to a varying extent, sometimes significantly, resulting in an unusual degree of uncertainty regarding the current true polio epidemiology. All of the countries reported postponements of immunization responses to cases, further increasing risk. In addition, routine immunisation has also been adversely affected by the pandemic in many countries. There is evidence that in some polio infected countries, the pandemic may yet to have peaked. As international travel begins to return, there is unknown risk of exportation of polioviruses. There are many other challenges ahead, such as the effect of COVID-19 on community trust and support for immunization, the possibility of other epidemics such as measles, the risks to front-line workers and how these can be managed, and the risk of immunization activities being associated with COVID-19 outbreaks, either truly or spuriously. On a positive note, the contribution of polio infrastructure, such as the National Emergency Operation Centre in Pakistan, to pandemic control efforts was significant. Going forward, the committee noted the opportunity to link polio eradication and pandemic response in positive ways. ConclusionThe Committee unanimously agreed that the risk of international spread of poliovirus remains a Public Health Emergency of International Concern (PHEIC) and recommended the extension of Temporary Recommendations for a further three months. However noting that many international borders are closed to prevent international spread of COVID-19, State Parties may not currently be able to enforce the Temporary Recommendations in all places. The Committee strongly urges countries subject to these recommendations to maintain a high state of readiness to implement them as soon as possible ensuring the continued safety of travelers as well as health professionals. The Committee recognizes the concerns regarding the lengthy duration of the polio PHEIC, but concludes that the current situation is extraordinary, with clear ongoing and increasing risk of international spread and ongoing need for coordinated international response. The Committee considered the following factors in reaching this conclusion:Rising risk of WPV1 international spread: The progress made in recent years appears to have reversed, with the Committee’s assessment that the risk of international spread is at the highest point since 2014 when the PHEIC was declared. This risk assessment is based on the following: the ongoing WPV1 exportation from Pakistan to Afghanistan, and from Afghanistan to Pakistan;ongoing rise in the number of WPV1 cases and positive environmental samples in both Pakistan and Afghanistan with formerly polio free areas within the countries reporting cases in 2020;the quickly increasing cohort of inaccessible unvaccinated children in Afghanistan, with the risk of a major outbreak imminent if nothing is done to access them;the urgent need to overhaul the leadership and strategy of the program in Pakistan, which although already commenced, is likely take some time to lead to more effective control of transmission and ultimately eradication;increasing community and individual resistance to the polio program. Rising risk of cVDPV international spread: The clearly documented increased spread in recent months of cVDPV2 demonstrate the unusual nature of the current situation, as international spread of cVDPV in the past has been very infrequent. The number of new emergences of cVDPV2 in Africa raises further concern. The risk of new outbreaks in new countries is considered very high. COVID-19: This unprecedented pandemic is likely to continue to substantially negatively impact the polio eradication program and outbreak control efforts. The need to take extra precautions to prevent COVID-19 transmission will probably have an impact on vaccination coverage, and also hamper polio surveillance activities leading to increased risk of missed transmission. Falling PV2 immunity: Global population mucosal immunity to type 2 polioviruses (PV2) continues to fall, as the cohort of children born after OPV2 withdrawal grows, exacerbated by poor coverage with IPV particularly in some of the cVDPV infected countries.Multiple outbreaks: The evolving and unusual epidemiology resulting in rapid emergence and evolution of cVDPV2 strains is extraordinary and not yet fully understood and represents an additional risk that is yet to be quantified.Weak routine immunization: Many countries have weak immunization systems that can be further impacted by various humanitarian emergencies including COVID19, and the number of countries in which immunization systems have been weakened or disrupted by conflict and complex emergencies poses a growing risk, leaving populations in these fragile states vulnerable to outbreaks of polio. Lack of access: Inaccessibility continues to be a major risk, particularly in several countries currently infected with WPV or cVDPV, i.e. Afghanistan, Nigeria, Niger, Somalia and Myanmar, which all have sizable populations that have been unreached with polio vaccine for prolonged periods.Population movement: While border closures may have mitigated the short term risk, conversely the risk once borders begin to be re-opened is likely to be higher. Risk categoriesThe Committee provided the Director-General with the following advice aimed at reducing the risk of international spread of WPV1 and cVDPVs, based on the risk stratification as follows:States infected with WPV1, cVDPV1 or cVDPV3, with potential risk of international spread.States infected with cVDPV2, with potential risk of international spread.States no longer infected by WPV1 or cVDPV, but which remain vulnerable to re-infection by WPV or cVDPV.Criteria to assess States as no longer infected by WPV1 or cVDPV:Poliovirus Case: 12 months after the onset date of the most recent case PLUS one month to account for case detection, investigation, laboratory testing and reporting period OR when all reported AFP cases with onset within 12 months of last case have been tested for polio and excluded for WPV1 or cVDPV, and environmental or other samples collected within 12 months of the last case have also tested negative, whichever is the longer.Environmental or other isolation of WPV1 or cVDPV (no poliovirus case): 12 months after collection of the most recent positive environmental or other sample (such as from a healthy child) PLUS one month to account for the laboratory testing and reporting periodThese criteria may be varied for the endemic countries, where more rigorous assessment is needed in reference to surveillance gaps (e.g. Borno State, Nigeria)Once a country meets these criteria as no longer infected, the country will be considered vulnerable for a further 12 months. After this period, the country will no longer be subject to Temporary Recommendations, unless the Committee has concerns based on the final report. TEMPORARY RECOMMENDATIONSStates infected with WPV1, cVDPV1 or cVDPV3 with potential risk of international spread WPV1Afghanistan (most recent detection 27 May 2020) Pakistan (most recent detection 8 June 2020)cVDPV1Malaysia (most recent detection 12 February 2020)Myanmar (most recent detection 9 August 2019)Philippines (most recent detection 28 November 2019)These countries should:Officially declare, if not already done, at the level of head of state or government, that the interruption of poliovirus transmission is a national public health emergency and implement all required measures to support polio eradication; where such declaration has already been made, this emergency status should be maintained as long as the response is required.Ensure that all residents and longterm visitors (i.e. > four weeks) of all ages, receive a dose of bivalent oral poliovirus vaccine (bOPV) or inactivated poliovirus vaccine (IPV) between four weeks and 12 months prior to international travel.Ensure that those undertaking urgent travel (i.e. within four weeks), who have not received a dose of bOPV or IPV in the previous four weeks to 12 months, receive a dose of polio vaccine at least by the time of departure as this will still provide benefit, particularly for frequent travelers.Ensure that such travelers are provided with an International Certificate of Vaccination or Prophylaxis in the form specified in Annex 6 of the IHR to record their polio vaccination and serve as proof of vaccination.Restrict at the point of departure the international travel of any resident lacking documentation of appropriate polio vaccination. These recommendations apply to international travelers from all points of departure, irrespective of the means of conveyance (e.g. road, air, sea).Further intensify cross border efforts by significantly improving coordination at the national, regional and local levels to substantially increase vaccination coverage of travelers crossing the border and of high risk cross border populations. Improved coordination of cross border efforts should include closer supervision and monitoring of the quality of vaccination at border transit points, as well as tracking of the proportion of travelers that are identified as unvaccinated after they have crossed the border.Further intensify efforts to increase routine immunization coverage, including sharing coverage data, as high routine immunization coverage is an essential element of the polio eradication strategy, particularly as the world moves closer to eradication.Maintain these measures until the following criteria have been met: (i) at least six months have passed without new infections and (ii) there is documentation of full application of high quality eradication activities in all infected and high risk areas; in the absence of such documentation these measures should be maintained until the state meets the above assessment criteria for being no longer infected.Provide to the Director-General a regular report on the implementation of the Temporary Recommendations on international travel. States infected with cVDPV2s, with potential or demonstrated risk of international spread Afghanistan (most recent detection 15 May 2020)Angola (most recent detection 9 February 2020)Benin (most recent detection 16 January 2020)Burkina Faso (most recent detection 30 March 2020)Cameroon (most recent detection 5 May 2020)Central African Republic (most recent detection 5 February 2020)Chad (most recent detection 9 May 2020) China (most recent detection 18 August 2019) Cote d’Ivoire (most recent detection 9 May 2020)Democratic Republic of the Congo (most recent detection 8 February 2020)Ethiopia (most recent detection 16 March 2020)Ghana (most recent detection 11 March 2020)Malaysia (most recent detection 22 January 2020)Mali (most recent detection 6 February 2020)Niger (most recent detection15 March 2020)Nigeria (most recent detection 1 January 2020)Pakistan (most recent detection 2 May 2020)Philippines (most recent detection 16 January 2020)Somalia (most recent detection 8 May 2020)Togo (most recent detection 3 May 2020)Zambia (most recent detection 25 November 2019)These countries should:Officially declare, if not already done, at the level of head of state or government, that the interruption of poliovirus transmission is a national public health emergency and implement all required measures to support polio eradication; where such declaration has already been made, this emergency status should be maintained.Noting the existence of a separate mechanism for responding to type 2 poliovirus infections, consider requesting vaccines from the global mOPV2 stockpile based on the recommendations of the Advisory Group on mOPV2.Encourage residents and longterm visitors to receive a dose of IPV four weeks to 12 months prior to international travel; those undertaking urgent travel (i.e. within four weeks) should be encouraged to receive a dose at least by the time of departure.Ensure that travelers who receive such vaccination have access to an appropriate document to record their polio vaccination status.Intensify regional cooperation and cross border coordination to enhance surveillance for prompt detection of poliovirus, and vaccinate refugees, travelers and cross border populations, according to the advice of the Advisory Group.Further intensify efforts to increase routine immunization coverage, including sharing coverage data, as high routine immunization coverage is an essential element of the polio eradication strategy, particularly as the world moves closer to eradication.Maintain these measures until the following criteria have been met: (i) at least six months have passed without the detection of circulation of VDPV2 in the country from any source, and (ii) there is documentation of full application of high quality eradication activities in all infected and high risk areas; in the absence of such documentation these measures should be maintained until the state meets the criteria of a ‘state no longer infected’.At the end of 12 months without evidence of transmission, provide a report to the Director-General on measures taken to implement the Temporary Recommendations. States no longer infected by WPV1 or cVDPV, but which remain vulnerable to re-infection by WPV or cVDPVWPV1none cVDPVMozambique cVDPV2 (most recent detection 17 December 2018)PNG cVDPV1 (most recent detection 6 November 2018)Indonesia cVDPV1 (most recent detection 13 February 2019) These countries should:Urgently strengthen routine immunization to boost population immunity.Enhance surveillance quality, including considering introducing supplementary methods such as environmental surveillance, to reduce the risk of undetected WPV1 and cVDPV transmission, particularly among high risk mobile and vulnerable populations.Intensify efforts to ensure vaccination of mobile and cross border populations, Internally Displaced Persons, refugees and other vulnerable groups.Enhance regional cooperation and cross border coordination to ensure prompt detection of WPV1 and cVDPV, and vaccination of high risk population groups.Maintain these measures with documentation of full application of high quality surveillance and vaccination activities.At the end of 12 months without evidence of reintroduction of WPV1 or new emergence and circulation of cVDPV, provide a report to the Director-General on measures taken to implement the Temporary Recommendations. Additional considerations Impact of COVID-19 on the polio program:The committee urges all countries, but particularly those at high risk of polio, to maintain a high level of polio surveillance throughout the ongoing pandemic, noting that the postponement of polio immunization campaigns whether preventive or in response to outbreaks may lead to an increase in polio transmission including international spread. There may be opportunities to strengthen polio and COVID-19 surveillance synergistically.Secondly, outbreak affected countries should resume immunization response campaigns as soon as feasibly possible. The planning and implementation of the response should employ a flexible approach whereby some activities are put on hold as the transmission of COVID-19 intensifies and then resumed as the COVID-19 transmission reverses back from community transmission to the interruption of COVID-19 transmission. Critically, campaigns should be planned and implemented in such a way that they protect front line polio workers and also the communities they serve so that COVID-19 transmission is not increased. This includes ensuring teams have access to appropriate personal protective equipment, teams are selected so that high risk workers are not put on the front-line, and that the risks related to the pandemic are factored into the selection and planning of areas targeted by polio campaigns. Given the risk of international spread, countries need to ensure that they are ready to use appropriate polio vaccines, as recommended by the Strategic Advisory Group of Experts on Immunization, in response to new outbreaks.The committee urged countries to maximize the use of polio assets to synergistically address the COVID19 pandemic, noting that polio affected countries may be vulnerable to poorer outcomes in the pandemic due to health care system fragility and poorer health status of the population generally. Lastly the pandemic should serve as a reminder to high risk countries with poor immunization coverage that infectious disease outbreaks can lead to social and economic disruption as well as straining the health care system, and countries can increase their population resilience and recovery through prioiritising robust immunization programmes. This is relevant not only to polio, but to all other vaccine preventable diseases particularly measles. In particular, countries whether eligible for Gavi support or not should plan to implement a second dose of IPV now being introduced to protect children from paralytic polio.Based on the current situation regarding WPV1 and cVDPV, and the reports provided by affected countries, the Director-General accepted the Committee’s assessment and on 3 July 2020 determined that the situation relating to poliovirus continues to constitute a PHEIC, with respect to WPV1 and cVDPV. The Director-General endorsed the Committee’s recommendations for countries meeting the definition for ‘States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread’, ‘States infected with cVDPV2 with potential risk for international spread’ and for ‘States no longer infected by WPV1 or cVDPV, but which remain vulnerable to re-infection by WPV or cVDPV’ and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus, effective 3 July 2020.
Introductory meeting of WHO’s Strategic and Technical Advisory Group for Tuberculosis
on 01/07/2020 at 3:21 pm
An introductory meeting of WHO’s Strategic and Technical Advisory Group for Tuberculosis (STAG-TB) was held on 24-25 June 2020. STAG-TB, which is comprised of 15 eminent experts from ministries of health, national TB programmes, academic and research institutions, civil society organizations, and communities and patients affected by TB. The group is led by Dr Ariel Pablos-Méndez as Chair, and provides strategic advice to WHO's Director-General and the Global TB Programme on its TB response.In his keynote address, WHO Director General Dr Tedros emphasized the important strategic role of STAG-TB in efforts to end TB especially in light of the current COVID-19 pandemic. He said, “Even at this difficult time, with COVID-19 threatening the world, WHO remains committed to meet the TB targets and driving high-level action and investment. Commitments must be kept to address all communicable disease threats, and reach the triple billion targets, despite the COVID-19 crisis. Doing so offers hope to end avoidable death and suffering for millions of people worldwide at risk from preventable and treatable diseases like TB.”The meeting was opened by Dr Ren Minghui, WHO Assistant Director-General, Universal Health Coverage, Communicable and Noncommunicable Diseases Division. The first day focused on briefings from the WHO Global TB Programme secretariat on ongoing WHO efforts towards ending TB, preparations underway for the development of the 2020 progress report of the UN Secretary General on TB, and the impact of the COVID-19 pandemic on the TB response. The second day included a special session of STAG-TB members with WHO Director-General Dr Tedros Adhanom Ghebreyesus. Key partners – Stop TB Partnership, Global Fund and UNITAID also participated in this session.Dr Ariel Pablos-Méndez, STAG-TB Chair highlighted the group’s commitment to guide WHO’s TB response. He emphasized, “We need to leverage existing synergies between TB and universal health coverage to save lives. This is especially critical in this time of crisis. STAG-TB is dedicated to providing strategic direction that will guide WHO in supporting countries to accelerate progress and investment to reach targets set by the UN High-level Meeting on TB.”Dr Tereza Kasaeva, Director of WHO’s Global TB Programme appreciated the role of STAG-TB, she said, “The STAG-TB provides a critical contribution to WHO, and the world, in combatting TB. We look forward to receiving strategic advice from STAG-TB during this, and coming, years on how the world can meet commitments to end the TB epidemic especially in the face of new threats”.The next meeting of the STAG-TB will be held in November 2020.
WHO announced as a Global Leader of the Generation Equality Action Coalition on ending gender-based violence
on 01/07/2020 at 1:26 pm
The Generation Equality Forum—a global gathering for gender equality, convened by UN Women and co-hosted by the governments of Mexico and France in partnership with civil society—today announced the leaders of the Generation Equality Action Coalitions, to achieve gender equality and all women’s and girls’ human rights. WHO, together with The United Nations Entity for Gender Equality and the Empowerment of Women (UN Women) have been invited to co-lead the Action Coalition focusing on ending gender-based violence. The Action Coalitions will deliver concrete and transformative change for women and girls around the world in the coming five years. They will focus on six themes that are critical for achieving gender equality. In addition to the coalition on gender-based violence there are five other coalitions on economic justice and rights, bodily autonomy and sexual and reproductive health and rights, feminist action for climate justice, technology and innovation for gender equality, and feminist movements and leadership. Adolescent girls and young women will be at the heart of each Action Coalition’s work. The 65 initial leaders of the Action Coalitions represent Member States, diverse feminist and women’s rights organizations, youth-led organizations, philanthropic entities, UN agencies and other international organizations ( full list here). The Action Coalitions’ leaders bring deep commitment to and experience in advancing gender equality and women’s human rights and reflect the different experiences and identities of women and girls from around the world. Further appointments of the Action Coalitions’ leaders will be made in the next few months, including private sector companies and youth-led organizations, to ensure intersectional and intergenerational leadership. The Action Coalitions’ leaders were selected by the Generation Equality Forum Core Group, which includes France, Mexico, Civil Society and UN Women. Five criteria were followed to select the leaders, including evidence of leaders’ commitment and past record of achievement in the respective Action Coalitions’ themes. The Action Coalitions are one of the key outcomes of the Generation Equality Forum that will kick off in Mexico City, Mexico, and culminate in Paris, France, in the first half of 2021. The Generation Equality Forum, accelerated by the Action Coalitions, will mobilize urgent action to make irreversible progress towards gender equality and women’s and girls’ human rights globally. This announcement comes as the world responds to the impacts of COVID-19, which is exacerbating gender and other inequalities and disproportionally affecting women and girls in all countries. In this context of the pandemic, the Generation Equality Forum and Action Coalitions are important and urgently needed to get through this pandemic, to recover faster, and build a more just, inclusive, and equitable future for everyone. Next stepsThe Action Coalitions’ leaders will come together in the coming months to co-design concrete, game-changing Blueprints for action to be implemented over the next five years. Beginning in September 2020, a set of virtual public conversations will mobilize and capture women’s and young people’s voices to inform the Action Coalitions. The Action Coalition Blueprints will then be refined at the Generation Equality Forum in Mexico City, during the first part of 2021, and officially launched at the Generation Equality Forum in Paris, later in 2021. The Action Coalitions aim to mobilize a broad support in addition to the leadership structure. A broad set of stakeholders will be involved in the design of the Action Coalitions during the next months and will be provided with opportunities to commit to transformative actions to advance gender equality and women’s rights. Violence against women is a major threat to global public health and human rights, cutting across boundaries of age, race, religion, ethnicity, disability, geography, culture and wealth. WHO is committed to working towards a world in which all women live their lives free of violence and discrimination. Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization&amp;amp;nbsp;
10th Ebola outbreak in the Democratic Republic of the Congo declared over; vigilance against flare-ups and support for survivors must continue
on 30/06/2020 at 1:24 pm
Today marks the end of the 10th outbreak of Ebola virus disease in the Democratic Republic of the Congo (Dem. Rep. of Congo). This long, complex and difficult outbreak has been overcome due to the leadership and commitment of the Government of the Dem. Rep. of Congo, supported by the World Health Organization (WHO), a multitude of partners, donors, and above all, the efforts of the communities affected by the virus. WHO congratulates all those involved in the arduous and often dangerous work required to end the outbreak, but stresses the need for vigilance. Continuing to support survivors and maintaining strong surveillance and response systems in order to contain potential flare-ups is critical in the months to come."The outbreak took so much from all of us, especially from the people of Dem. Rep. of Congo, but we came out of it with valuable lessons, and valuable tools. The world is now better-equipped to respond to Ebola. A vaccine has been licensed, and effective treatments identified,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus.“We should celebrate this moment, but we must resist complacency. Viruses do not take breaks. Ultimately, the best defence against any outbreak is investing in a stronger health system as the foundation for universal health coverage.”The outbreak, declared in North Kivu on 1 August 2018, was the second largest in the world, and was particularly challenging as it took place an active conflict zone. There were 3470 cases, 2287 deaths and 1171 survivors. Led by the Dem. Rep. of Congo Government and the Ministry of Health and supported by WHO and partners, the more than 22-month-long response involved training thousands of health workers, registering 250 000 contacts, testing 220 000 samples, providing patients with equitable access to advanced therapeutics, vaccinating over 303 000 people with the highly effective rVSV-ZEBOV-GP vaccine, and offering care for all survivors after their recovery.The response was bolstered by the engagement and leadership of the affected communities. Thanks to their efforts, this outbreak did not spread globally. More than 16 000 local frontline responders worked alongside the more than 1500 people deployed by WHO. Support from donors was essential, as was the work of UN partner agencies, national and international NGOs, research networks, and partners deployed through the Global Outbreak Alert and Response Network. Hard work to build up preparedness capacities in neighbouring countries also limited the risk of the outbreak expanding.Work will continue to build on the gains made in this response to address other health challenges, including measles and COVID-19. “During the almost two years we fought the Ebola virus, WHO and partners helped strengthen the capacity of local health authorities to manage outbreaks,” said Dr Matshidiso Moeti, WHO Regional Director for Africa.“The Dem. Rep. of Congo is now better, smarter and faster at responding to Ebola and this is an enduring legacy which is supporting the response to COVID-19 and other outbreaks.” As countries around the world face the COVID-19 pandemic, the Dem. Rep. of Congo Ebola response provides valuable lessons. Many of the public health measures that have been successful in stopping Ebola are the same measures that are now essential for stopping COVID-19: finding, isolating, testing, and caring for every case and relentless contact tracing. In Dem. Rep. of Congo, community workers were provided with training and a smartphone data collection app that enabled them to track contacts and report in real time rather than fill in laborious paper reports. Even when violence locked down cities, the community workers, many of them local women, continued to track and trace contacts using the application, something that was crucial for ending this outbreak.While this 10th outbreak in Dem. Rep. of Congo has ended, the fight against Ebola continues. On 1 June 2020, seven cases of Ebola were reported in Mbandaka city and neighbouring Bikoro Health Zone in Equateur Province and an 11th outbreak was declared. WHO is supporting the government-led response with more than 50 staff already deployed and more than 5000 vaccinations already administered.WHO salutes the thousands of heroic responders who fought one of the world’s most dangerous viruses in one of the world’s most unstable regions. Some health workers, including WHO experts, paid the ultimate price and sacrificed their lives to the Ebola response. WHO thanks the many partners who supported the Government-led responseNote to EditorsWHO thanks the donors who provided funding to WHO for the Ebola response under the Strategic Response Plans: African Development Bank, Bill & Melinda Gates Foundation, Canada, China, Denmark, ECHO, European Commission/DEVCO, Gavi, the Vaccine Alliance, Germany, Ireland, Italy, Luxembourg, Norway, Paul Allen Foundation, Republic of Korea, Sweden, Switzerland, Susan T Buffett Foundation, United Kingdom DFID, UN CERF, United StatesID/OFDA, US CDC, Wellcome Trust, World Bank, World Bank Pandemic Emergency Financing Facility. Several donors also provided funding to the WHO Contingency Fund for Emergencies in recognition of the critical role the fund has played in responding to the Ebola outbreak.
WHO urges countries to expand access to rapid molecular tests for the detection of TB and drug-resistant TB
on 30/06/2020 at 1:05 pm
The World Health Organization (WHO) is urging countries to expand access to rapid molecular tests for the detection of TB and drug-resistant TB in updated consolidated guidelines, released today. The guidelines are accompanied by an operational handbook to facilitate rapid implementation and roll out of rapid molecular tests by national TB programmes, ministries of health and technical partners.“The use of rapid molecular assays as the initial test to diagnose TB is recommended instead of sputum smear microscopy as they have high diagnostic accuracy and will lead to major improvements in the early detection of TB and drug-resistant TB,” said Dr Tereza Kasaeva, Director of WHO’s Global TB Programme. “We now need to urgently ensure universal access to these rapid molecular tests. This will impact positively on reducing transmission and enabling faster access to accurate life-saving treatment that will lead to better outcomes for those affected.”The consolidated guidelines and the associated operational handbook recommend key updates of the approaches to diagnose TB including:The use of Xpert MTB/RIF assay, Xpert Ultra assay and Truenat assay as the initial test to diagnose pulmonary TB and to detect rifampicin resistance. This replaces smear microscopy and culture.The use of Xpert MTB/RIF assay and Xpert Ultra assay for improved diagnosis of TB and rifampicin resistance in children, in specific specimens such as sputum, stool, nasopharyngeal and gastric specimensThe use of Xpert MTB/RIF assay and Xpert Ultra assay for improved diagnosis of TB and rifampicin resistance in patients with broad range of extrapulmonary TB.The Xpert MTB Rif assay has been used worldwide since 2010, while the Xpert Ultra assay and Truenat assay are new technologies. The above updates were signaled in January 2020 through a Rapid Communication from WHO in advance of the publication of the updated guidelines. The purpose was to help national TB programmes and other stakeholders plan and prepare in advance for the rapid transition to new diagnostic tools at country level.Globally, diagnosis of TB and drug-resistant TB remains a challenge with a third of people with TB and two-thirds of people with drug-resistant TB not being detected. Accelerated efforts to diagnose TB and drug-resistance are essential to end the global TB epidemic and achieve the targets of the political declaration of the UN high-level meeting, the WHO End TB Strategy, the UN Sustainable Development Goals, universal health coverage and the triple billion targets of WHO’s General Programme of Work.
Public call for data on diagnostic accuracy on nucleic acid amplification tests to detect TB and resistance to selected anti-TB agents
on 30/06/2020 at 12:22 pm
Nucleic acid amplification tests (NAAT) are promising technologies for the rapid and accurate detection of TB and resistance to selected anti-TB agents. In December 2020, the World Health Organization (WHO) will convene a Guidelines Development Group (GDG) meeting to update its diagnostic guidelines on the use of NAATs to detect TB and resistance to selected anti-TB agents. Ahead of this meeting, WHO will commission reviews of relevant evidence on diagnostic accuracy for several NAAT assays.The following NAAT assays or classes of NAAT assays will be discussed by the GDG:Centralized assays that present end-to-end solutions for detection of TB and resistance to rifampicin and isoniazid (cDST: Index test 1);Cartridge-based technology for isoniazid and second-line drug resistance detection (XDR cartridge: Index test 2);Hybridization-based technology for pyrazinamide resistance detection (PZA LPA: Index test 3).To enable this process, WHO is issuing a public call for data, appealing to industry, researchers, national TB programmes and other agencies to provide suitable evidence for the performance of these technologies. The obtained data will be essential to facilitate the process of WHO policy updates.Please send relevant data by 1st August 2020, to email@example.com. For more information on the parameters of the datasets, variables, and the process see below:Annex 1: Data requirementsIndex test 1: Centralized assays that present end-to-end solutions for detection of TB and resistance to rifampicin and isoniazid (cDST platforms).Desirable characteristics of the test: (a) Sample preparation workflow included; (b) Automated DNA extraction; (c) Automated PCR preparation; (d) Automated result interpretation; (c) Capacity per run: ≥24 tests; (d) Time from sample to full MDR-TB diagnosis: <12 hours; (e) Minimal desirable drug resistance detection: at least to INH and RIF.Study type: Clinical evaluation studies to confirm diagnostic performance on clinical samples.Study population: Random sample of unselected patients with signs and symptoms of TB, requiring evaluation for TB and/or resistance to isoniazid and rifampicin in sites of intended use.Reference standard: At a minimum, result of a single sputum culture and phenotypic DST, wherever applicable (liquid or solid, with speciation) should be included for each result of Index test 1. The use of a genotypic sequencing results where available will have an added value to confirm the presence of mutations in addition to phenotypic DST results.Index test 2: Cartridge-based technology for isoniazid and second-line drug resistance detection (XDR cartridge);Desirable characteristics of the test: (a) Automated real-time PCR; (b) Automated result interpretation; (b) Capacity per run: ≥ 4 tests; (c) Time test results: <4 hours; (d) Minimal desirable drug resistance detection: at least to INH and FQ.Study type: (a) Analytical validation studies measuring accuracy, precision, and reproducibility of the test in contrived specimens or panels, covering all key mutations to isoniazid and second-line drugs. (b) Clinical evaluation studies to confirm diagnostic performance on clinical samples.Study population: Patients with detected TB, requiring evaluation for resistance to isoniazid and second-line anti-TB agents in sites of intended use.Reference standard: At a minimum, result of a single sputum phenotypic DST (liquid or solid, with speciation) should be included for each result of Index test 2. The use of a genotypic sequencing results where available will have an added value to confirm the presence of mutations in addition to phenotypic DST results.Index test 3: Hybridization-based technology for pyrazinamide resistance detection (PZA LPA).Desirable characteristics of the test: (a) Automated or manual hybridization methodology; (b) Automated or manual result interpretation (c) Time from sample to test results: <24 hours; (d) Minimal desirable drug resistance detection: at least to PZA.Study type: (a) Analytical validation studies measuring accuracy, precision, and reproducibility of the test in contrived specimens or panels, covering all key mutations to pyrazinamide; (b) Clinical evaluation studies to confirm diagnostic performance on clinical samples;Study population: Patients with detected TB and resistance to rifampicin, requiring evaluation for resistance to pyrazinamide in sites of intended use;Reference standard: At a minimum, result of a single sputum phenotypic DST (liquid or solid, with speciation) should be included for each result of Index test 3. The use of a genotypic sequencing results where available will have an added value to confirm the presence of mutations in addition to phenotypic DST results.
WHO speaks at the European Parliament on the COVID-19 response
on 30/06/2020 at 7:44 am
On June 25, WHO Director General Dr Tedros Adhanom Ghebreyesus and Dr Hand Kluge, Regional Director of WHO Europe, spoke at the European Parliament Committee for Environment, Public Health and Food Safety (ENVI) on the fight against COVID-19 and the global response and highlighted the leadership of the European Union during this unprecedented time. “The EU is in a unique position to provide global leadership in defining the “new normal” as part of the global recovery”, Dr Tedros said. He reminded parlamentarians, that “although the situation in Europe has improved, globally it is still getting worse” and he added that “In the first month of this outbreak, less than 10,000 cases were reported to WHO. In the last month, almost 4 million cases have been reported.”.The pandemic is showing how essential it is for governments at all levels, including local governments, to strengthen their capacity for prevention, preparedness and response. But plans for the post-COVID-19 recovery, and to reduce the risk of future epidemics, must go further upstream than early detection and control of disease outbreaks – “they must also lessen our impact on the environment, to reduce risk at the source”, Dr Tedros stressed. In this regard, Dr Tedros welcomed the Team Europe approach and the European Union plans for a greener recovery, bringing nature back in our lives. He also praised the Global Coronavirus Response pledging campaign launched by the EU, which has so far raised €9.8 billion, and said more is needed.Dr Kluge emphasized the complementarities and synergies between the European Programme of Work, entitled United Action for Better Health” entitled, in supporting WHO’s Thirteenth General Programme of Work (GPW13) and the EU4Health Programme of the European Commission. Dr Kluge warned parliamentarians about a second wave in Europe and that countries should be prepared. In this regard, he announced that the WHO European Region has started an ACTION REVIEW, gathering lessons learned in order to develop policy options to help countries to prepare for the Autumn. The Regional Director underlined that “health systems based on strong primary health care are the foundation for health security and universal health coverage” and that national routine immunization programmes needs to be maintained during the pandemic, he said.
Partners in health: Germany and France commit to increased support to WHO affirming the Organization’s crucial role in global public health
on 30/06/2020 at 7:29 am
Germany and France have reconfirmed their political, financial and technical support to WHO. His Excellency Olivier Véran, Minister for Solidarity and Health of the Republic of France, and His Excellency Jens Spahn Minister of Health of the Federal Republic of Germany, met with WHO Director General Dr Tedros Adhanom Ghebreyesus in Geneva on 25 June to discuss the status of the global COVID-19 pandemic and measures to help countries where it continues to spread.“WHO is honoured to welcome you both here today,” said Dr Tedros during the press conference that followed the tripartite meeting, “we offer our sincere thanks for your expression of solidarity and support. We’re getting today all the support we need, political and financial. I would like to express my gratitude.”Germany will lead the EU Presidency for the next six months. “Global health and managing the pandemic will be key themes,” said Minister Spahn. “This is why I came to discuss the Presidency plans and ways to support WHO during this critical time. Germany remains a strong supporter and a friend; this is why I am here today.” Germany will contribute an additional EUR 41.4 million to WHO‘s core work, and an additional EUR 200 million towards the implementation of the COVID-19 Strategic Preparedness and Response Plan. This follows Germany’s pledge in May of EUR 110 million to WHO in support of the Access to COVID-19 Tools (ACT) Accelerator, a Global Collaboration to Accelerate the Development, Production and Equitable Access to New COVID-19 diagnostics, therapeutics and vaccines.“The world needs interconnected crisis management, we need a strong, efficient, transparent WHO, more than ever, that is able to lead and coordinate the response in a global crisis,” added Minister Spahn. “Germany will do its part to give WHO the political, financial and technical support that is needed.”Minister Véran reaffirmed France’s confidence in the Organization as the leading global public health agency and its crucial role in the response to epidemic diseases and in this case the COVID-19 pandemic. “I am also here to announce increased support to the work WHO, firstly with contribution in the amount of EUR 90 million towards the establishment of the WHO Academy, a centre of excellence that brings together international cooperation in the area of training and innovation”. He also highlighted the importance of the Germany-France partnership – both Member States of WHO and of the European Union -- saying that international cooperation is needed today more than ever. On this occasion Minister Véran also confirmed President Macron’s commitment during the ACT Accelerator Marathon on 4 May to support WHO’s coordination role and to provide and additional contribution of EUR 50 million for 2020-2021.Germany and France both have longstanding partnerships with WHO and are strong supporters of global public health. Chancellor Angela Merkel was the first world leader to invite WHO to the G20 in 2017 under Germany’s leadership, thus highlighting importance of health for all people all around the world. Germany was at the center of the development of the Global Action Plan for Healthy Lives and Well-Being for All, to drive progress towards the Sustainable Development Goals. Germany and WHO have engaged together on a multi-year Collaborative Programme providing decisive support in particular to implementation of Sustainable Development Goal 3 to ensure healthy lives and well-being for all people of all ages, health systems strengthening, health emergencies preparedness, anti-microbial resistance and access to medicine.For more than 50 years, France has hosted the International Agency for Research on Cancer in Lyon. France has also hosted the WHO Lyon Office for Country readiness strengthening since 2001. More recently, France and WHO signed an agreement to establish the WHO Academy, also in Lyon, which will be a state-of-the-art training centre, bringing the latest lifelong learning innovations to the global health sector.In addition to their political, financial and technical support, Germany and France have also donated masks, respirators and other medical supplies and equipment to vulnerable populations still suffering from the COVID-19 pandemic.
Timeline of WHO’s response to COVID-19
on 29/06/2020 at 2:24 pm
WHO provides this timeline of the organization’s COVID-19 response activities for general information. WHO will update the timeline on a regular basis and in light of evolving events and new information. Unless noted otherwise, country-specific information and data are as reported to WHO by its Member States. This timeline continues in the spirit of, and supersedes, the WHO Rolling Updates and the WHO Timeline statement published in April 2020. It is not intended to be exhaustive and does not contain details of every event or WHO activity. As of 29 June 2020, the following milestones and events focused on COVID-19 have taken place: • The Director-General and Executive Director of the WHO Health Emergencies Programme have held 74 media briefings. The Director-General's opening remarks, transcripts, videos and audio recordings for these media briefings are available online. • There have been 23 Member State Briefings and information sessions. • EPI-WIN, WHO’s information network for epidemics, has convened 60 technical webinars, making available 287 expert panellists to more than 13,500 participants, from more than 120 countries and territories, with representation from as many as 460 organizations. • The OpenWHO platform has had more than 2.7 million enrolments in its COVID-19 courses. Free training is available on 13 different topics translated into 31 languages to support the coronavirus response, for a total of 100 COVID-19 courses. • WHO’s landscape of COVID-19 candidate vaccines lists 17 candidate vaccines in clinical evaluation and 132 in preclinical evaluation. In addition to the selected guidance included below, all of WHO’s technical guidance on COVID-19 can be found online here. All events listed below are in the Geneva, Switzerland time zone (CET/CEST). Note that the dates listed for documents are based on when they were finalised and timestamped.
8th TRIAD Meeting: Statement
on 29/06/2020 at 12:34 pm
The 2020 “Triad Statement” was issued at the close of the 8th biennial meeting of the WHO, the International Confederation of Midwives, and the International Council of Nurses. In 2020 the Triad Meeting took place under the dual spotlight of the International Year of the Nurse and the Midwife and the COVID-19 pandemic. The resulting Triad Statement focuses on actions that participants in their respective roles agree to take to support WHO Member States in strengthening nursing and midwifery towards priority health targets, including responding to COVID-19 and achieving universal health coverage.
Final Statement on the 8th meeting of the International Health Regulations (2005)
on 26/06/2020 at 4:57 pm
Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo (provinces of Ituri, North Kivu, and South Kivu) on 26 June 2020 The 8th meeting of the Emergency Committee, convened by the WHO Director-General under the International Health Regulations (IHR) (2005) to review the Ebola virus disease (EVD) outbreak in the Ituri, North Kivu, and South Kivu provinces of the Democratic Republic of the Congo (Dem. Rep. of Congo), took place on Friday, 26 June 2020, from 13:00 to 15:50 Geneva time (CEST). The Committee’s role is to give advice to the Director-General, who makes the final decision on the determination of a Public Health Emergency of International Concern (PHEIC) and issues Temporary Recommendations as appropriate.Proceedings of the meetingMembers and advisors of the Emergency Committee were convened by teleconference.The Secretariat welcomed the Committee and thanked them for their support. The Director-General welcomed the Committee and expressed gratitude for all who have responded to this outbreak. Representatives of WHO’s legal department and the department of compliance, risk management, and ethics briefed the Committee members on their roles and responsibilities. Committee members were reminded of their duty of confidentiality and their responsibility to disclose personal, financial, or professional connections that might be seen to constitute a conflict of interest. Each member who was present was surveyed and no conflicts of interest were judged to be relevant to the meeting. The meeting was turned over to the Chair, Dr Preben Aavitsland. Dr Aavitsland also welcomed the Committee, outlined the objectives of the meeting, and introduced the presenters.Presentations were made by a representative of the Ministry of Health of the Dem. Rep. of Congo and the WHO Secretariat to update the Committee on the situation. The Dem. Rep. of Congo Ministry of Health provided an update of the epidemiological situation. As of 23 June 2020, a total of 3 470 EVD cases were reported from 29 health zones, including 3 317 confirmed and 153 probable cases, of which 2 287 cases died (CFR 66%). Since the last reported case on 27 April 2020, no new confirmed or probable cases of EVD have been reported. On 25 June 2020, the Dem. Rep. of Congo Ministry of Health declared that human-to-human transmission of Ebola virus had ended in Ituri, North Kivu, and South Kivu provinces. The Ministry of Health of Dem. Rep. of Congo notes that a separate EVD outbreak is occurring in the Equateur Province, not epidemiologically related to the outbreak in the Ituri, North Kivu, and South Kivu provinces.The Dem. Rep. of Congo Ministry of Health is implementing their national response plan to strengthen surveillance, laboratory diagnostic capacities, infection prevention and control (IPC), risk communication and community engagement (RCCE), the EVD survivor care programme, and provincial health departments’ operational capacities.The WHO Secretariat presented the WHO risk assessment and context. Based on the evolution of the outbreak, current epidemiology, and response in Ituri, North Kivu, and South Kivu provinces, the overall national and regional risk levels remain moderate. The global risk level remains low.WHO noted that regional preparedness capacities built for EVD response, such as coordination mechanisms; response plans; laboratory diagnostic capacity; rapid response teams; and community-based surveillance systems, are also being used to facilitate a robust COVID-19 response. Remaining challenges include the need for continued human and financial resources to maintain prevention, preparedness, response and control activities, such as the EVD survivor care programme; the volatile security situation; the new EVD outbreak in Equateur Province; and the concurrent burden of COVID-19, cholera, and measles. Although the outbreak in Ituri, North Kivu, and South Kivu provinces has been officially declared over, the detection of a new EVD outbreak in Equateur Province highlights the potential for re-introduction from animal reservoirs. The Dem. Rep. of Congo and at-risk countries need to maintain vigilance to mitigate the risk of EVD re-emergence as well as to rapidly detect and respond to any new cluster. Context and DiscussionThe Committee congratulated the Ministry of Health on the conclusion of the EVD outbreak in Ituri, North Kivu, and South Kivu provinces. The Committee conveyed their strong appreciation to the World Health Organization for their support in ending this challenging outbreak. The Committee also thanked the health workers, donors, and all partners who have supported the successful response and recognized the international collaboration and strong solidarity among Dem. Rep. of Congo, neighbouring countries, WHO, and partners. The Committee noted that the genetic sequencing has confirmed that the EVD outbreaks in the Ituri, North Kivu, and South Kivu provinces and the Equateur province are epidemiologically distinct events. The Committee highlighted the importance of the 90-day national response plan which includes maintaining intensive surveillance, response capacity, and follow-up with EVD survivors. Dem. Rep. of Congo and partners are engaging in all measures to reduce the potential for a resurgence in Ituri, North Kivu, and South Kivu provinces. The Committee noted the importance of the EVD survivor care programme and continued RCCE activities, which will continue to be conducted by locally trained staff in each province with support from national staff as needed. The Committee expressed concern over the lack of prioritized resources to operationalize the 90-day national response plan and maintain long-term local capacity for prevention and response. Financial and human resources of Dem. Rep. of Congo, WHO, and partners are challenged by the concurrent COVID-19, cholera, and measles outbreaks. The Committee encouraged Dem. Rep. of Congo, WHO, and partners to harmonize EVD, cholera, measles, and COVID-19 prevention and control activities. Conclusions and AdviceThe Committee agreed that the current situation in the Ituri, North Kivu, and South Kivu provinces no longer constitutes a public health emergency of international concern. The Committee emphasized the importance of continued donors’ funding and human resources to operationalize the 90-day day national response plan.The Committee provided the following advice to the Director-General for his issuance as revised Temporary Recommendations, in accordance with Article 15(1) of the IHR (2005) “…Temporary Recommendations may be modified or extended as appropriate, including after it has been determined that a public health emergency of international concern has ended, at which time other temporary recommendations may be issued as necessary for the purpose of preventing or promptly detecting its recurrence These Temporary Recommendations shall automatically expire three months after their issuance.” The Committee provided the following advice to the Director-General for his issuance as revised Temporary Recommendations under the IHR (2005).For Dem. Rep. of Congo:Operationalize their 90-day national response plan and ensure the appropriate human and financial resources are available for implementation throughout the full duration. Continue their EVD survivor care programme which provides clinical, biological, and social support to survivors. Continue the use of the Community Action Cells, or comparable community-level resources, for locally based RCCE to address potential EVD flare-ups and spillover events. Leverage resources, as needed by integrating EVD RCCE activities with concurrent response efforts related to outbreaks of measles, cholera, and COVID-19. Take note of the upcoming Strategic Advisory Group of Experts on Immunization (SAGE) recommendations on the use of EVD vaccines. Develop an EVD prevention and control plan to sustain preparedness and response capacity beyond the initial 90-day national response plan. Neighbouring countries: Continue to strengthen their surveillance for EVD to prevent the risk of potential spread. For WHO: Continue to encourage research on animal reservoirs and the potential for spillover events. Continue engagement with countries and partners, including industry, to establish and maintain a strategic global stockpile for EVD vaccines. Collect and publish lessons learned with Dem. Rep. of Congo and partners on this EVD outbreak, including on the effectiveness of vaccination and other interventions, and challenges related to emergency response in the context of civil unrest and insecurity. Based on this advice, the report made by the affected State Party and the currently available information, the Director-General accepted the Committee’s assessment and on 26 June 2020 declared the end of the Public Health Emergency of International Concern (PHEIC) for this event.The Director-General accepted the Committee’s advice and issued them as Temporary Recommendations under IHR (2005), effective 26 June 2020. The Director-General thanked the Committee Members and Advisors for their advice throughout the outbreak.
IOC joins forces with WHO and the United Nations to fight COVID-19
on 26/06/2020 at 4:21 pm
The International Olympic Committee and WHO together with the United Nations launch a partnership to encourage individuals and communities around the world to be #HEALTHYTogether. The three partners and Olympic athletes will spotlight the global collaboration needed to stay healthy and reduce the spread and impact of COVID-19.
on 26/06/2020 at 11:55 am
The tools developed will benefit the whole world, and by saving lives and reducing severe COVID-19 disease, contribute to the goal of protecting health systems and restoring full societal and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.The consolidated investment case calls for US$31.3 billion over the next 12 months. US$3.4 billion has been contributed to date, resulting in a funding gap of US$27.9 billion, of which $13.7 billion is urgently needed.Pillar plans published today show a path to the accelerated development, equitable allocation, and scaled up delivery of 500 million tests to LMIC’s by mid-2021, 245 million courses of treatments to LMICs by mid-2021, and 2 billion vaccine doses, of which 1 billion will be purchased for LMICs, by the end of 2021.Today, the Access to COVID-19 Tools Accelerator (ACT-Accelerator) published its consolidated investment case, alongside the costed plans of the member organizations.Launched at the end of April 2020, at an event co-hosted by the Director-General of the World Health Organization, the President of France, the President of the European Commission, and The Bill & Melinda Gates Foundation, the ACT-Accelerator brings together governments, health organizations, scientists, businesses, civil society, and philanthropists who have joined forces to speed up an end to the pandemic.Since the ACT-Accelerator was launched, the partner organizations have moved fast to develop costed and implementable plans designed to contribute to the end of the pandemic through the accelerated development, equitable allocation, and scaled up delivery of new tools to reduce rapidly mortality and severe disease, protecting health systems and restoring full societal and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.ACT-Accelerator investment case and costed plansThe ACT-Accelerator’s investment case and the plans published by the organizations leading each of the ‘pillars’ show a path to the accelerated development, equitable allocation, and scaled up delivery of 500 million diagnostic tests to LMIC’s by mid-2021, 245 million courses of treatments to LMICs by mid-2021, and 2 billion vaccine doses, of which 50% will go to LMICs by the end of 2021.To achieve this, the costed plans presented today call for US $31.3 billion in funding for diagnostics, therapeutics and vaccines, of which US$3.4 billion has so far been pledged. An additional US$27.9 billion is therefore needed, including US$13.7 billion to cover immediate needs (i.e. US$17.1 billion is immediately required, of which US$3.4 billion has been pledged). The investment required is significant, but it pales in significance when compared to the cost of COVID-19: the total cost of the ACT-Accelerator's work is less than a tenth of what the IMF estimates the global economy is losing every month due to the pandemic. 468,000 thousand people have already lost their lives.The tools developed will benefit the whole world; the ACT-Accelerator pillars will also buy and deliver tools to ensure that LMIC’s have access.The ACT-Accelerator’s investment case is available here.ACT-Accelerator pillarsThe ACT-Accelerator is led by the work of partner organizations collaborating under four pillars.The diagnostics pillar is co-led by FIND and the Global Fund to Fight AIDS, Tuberculosis and Malaria, and aims to save 9 million lives and avoid 1.6 billion further infections through the power of equitable access to simple, accurate and affordable tests. With sufficient funding, it can bring to market 2–3 high-quality rapid tests, train 10,000 healthcare professionals across 50 countries, and establish testing for 500 million people in low- and middle-income countries. Its success will be determined by how quickly test, trace and isolate strategies can be put in place, to minimize disruption of health services and prepare countries for the effective roll-out of therapeutics and vaccines once available. The investment case is available here.The therapeutics pillar is led by Unitaid and the Wellcome Trust (on behalf of the COVID-19 Therapeutics Accelerator) and seeks to accelerate the development and equitable delivery of treatments at all stages of disease, ensuring they are accessible to all, regardless of geography and level of economic resource. It targets development, manufacture, procurement and equitable distribution of 245 million courses of treatment for populations in Low and Middle Income Countries within 12 months. The investment case is available here.The vaccine pillar, combines CEPI’s leadership in vaccine development and investment in manufacturing with GAVI’s track record in revolutionizing access and delivery, and WHO’s oversight of regulation, policy and allocation. Its role is to ensure that vaccines are developed as rapidly as possible, manufactured at the right volumes without compromising on safety and delivered to those that need them most. The current estimate to deliver 2 billion doses by the end of 2021, assuming a safe and effective vaccine is developed in the near future, is up to US$18.1 billion. In addition, 950 million doses will need to be procured by self-financing high-income countries and upper middle-income countries through the COVAX Facility. These numbers will become clearer once we get a better idea of, among other factors, the technology that the successful vaccine candidates will be based on and the number of doses required to protect people from COVID-19. The investment case is available here.The health systems connector is the fourth pillar of the ACT-Accelerator and supports the other three by ensuring that health systems and local community networks can fully utilize these and other essential tools in their battle against COVID-19. This pillar is led by the World Bank and the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and supported by the WHO. It aims to build capacity – such as laboratory capacity, training for laboratory and health staff and management of protective equipment for health workers – needed to deploy the new tools effectively when they are ready. It also works on system innovations to complement the rollout of products, such as contact tracing, social distancing and isolation approaches as well as community engagement needed to sustain them. Global health security and the fight against COVID-19 depends on shoring up health systems around the world, now. Call to actionSince its launch, many governments and companies have signaled commitment to the ACT-Accelerator and made financial pledges. To date, contributing countries have committed a total US$3.4. The funding gap is US$ 27.9 billion.On 27 June the Global Goal: Unite for Our Future, campaign, concert & summit will be calling on citizens to tackle global injustices by using our collective voice to drive change for everyone, everywhere. World leaders, corporations and philanthropists will announce new commitments to help develop equitable distribution of COVID-19 tests, treatments and vaccines, as well as rebuild communities devastated by the pandemic. Unite with Global Citizen, the European Commission, top artists and global leaders to end COVID-19, build equity for all and fight for the world we want. Link: https://www.globalcitizen.org/en/connect/globalgoalunite/Notes to EditorsThe Access to COVID-19 Tools ACT-Accelerator, is a new, groundbreaking global collaboration to accelerate the development, production, and equitable access to COVID-19 diagnostics, therapeutics, and vaccines. It was set up in response to a call from G20 leaders in March and launched by the WHO, EC, France and The Bill & Melinda Gates Foundation in April 2020.The ACT-Accelerator is not a decision-making body or a new organization, but works to speed up collaborative efforts among existing organizations to end the pandemic. It is a framework for collaboration that has been designed to bring key players around the table with the goal of ending the pandemic as quickly as possible by reducing COVID-19 mortality and severe disease through the accelerated development, equitable allocation, and scaled up delivery of vaccines, therapeutics and diagnostics, thereby protecting health systems and restoring societies and economies in the near term. It draws on the experience of leading global health organizations which are tackling the world’s toughest health challenges, and who, by working together, are able to unlock new and more ambitious results against COVID-19. Its members share a commitment to ensure all people have access to all the tools needed to defeat COVID-19 and to work with unprecedented levels of partnership to achieve it.The ACT-Accelerator has four areas of work: diagnostics, therapeutics, vaccines and the health system connector. Cross-cutting all of these is the workstream on Access & Allocation. An additional $1.7 billion has been pledged for health systems. The timeframe is 18 months for the vaccines pillar. For more information please see ACT-Accelerator.For media enquiries: ACTacceleratormedia@who.int
Sustained decline in sleeping sickness cases puts elimination within reach
on 25/06/2020 at 10:32 am
Countries endemic for human African trypanosomiasis, HAT (also known as sleeping sickness) continue to report fewer cases, indicating that the disease is well on course for elimination as a public health problem by the end of this year. Latest data show only 980 cases were reported to the World Health Organization (WHO) in 2019 which include the numbers for both the rhodesiense and gambiense forms of the disease.
The World Health Organization reminds public to remain vigilant through Mr Bean’s Essential COVID-19 Checklist
on 22/06/2020 at 9:51 am
Public Service Announcement reminds people about the importance of washing hands, physical distancing and showing kindness The World Health Organization (WHO), Project Everyone and Tiger Aspect Productions have partnered to launch a Public Service Announcement (PSA) using global comedy cartoon star, Mr Bean. With cases of COVID-19 continuing to rise globally, “Mr Bean’s Essential COVID-19 Checklist” is a reminder to people about the importance of washing hands, physical distancing and demonstrating kindness to their neighbours. The PSA features a cartoon sketch of Mr Bean comically tackling a pesky roller blind to finally reveal a number of essential tips to protect people against COVID-19. Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, said: “COVID-19 affects every walk of human life, and we need to use all tools and avenues at our disposal to share life-saving information with all people around the world. I am grateful for the support of the team behind Mr Bean for lending your voice and talents to spread vital advice on physical distancing, hygiene and knowing the symptoms.”The PSA is voiced by Mr Bean star, Rowan Atkinson, who created the Mr Bean character to be "a child in a grown man's body" when he was at Oxford University along with filmmaker and Sustainable Development Goal advocate Richard Curtis. Mr Bean, which was originally broadcast in the 1990s before transforming into an animated series, has since expanded on a global scale with 96 million Facebook followers globally and major fanbases across India, Brazil and Indonesia. Mr Bean also celebrates his 30th anniversary in 2020.The PSA was coordinated by Project Everyone, a not-for-profit agency devised by Richard Curtis working to put the power of communications behind the UN’s Sustainable Development Goals.Richard Curtis said: “We are delighted to work with the WHO on this Mr Bean sketch and to support health messaging around COVID-19. In 2015 193 world leaders committed to 17 Global Goals to end poverty, inequality and climate change by 2030. Good Health and Wellbeing is Goal 3 and central to achieving all of the Global Goals. It’s key that we work with creative partners - and that all sectors come together to continue to get messages out about how we can tackle COVID-19 and build back a better world where the Global Goals remain the guiding plan to be achieved by 2030. I’m not QUITE sure which sector Mr Bean belongs too - but we're delighted to have him on board.” NOTES TO EDITORS Media contactsWHO: firstname.lastname@example.orgProject Everyone: email@example.com --------------About the World Health OrganizationThe World Health Organization directs and coordinates international health within the United Nations system. Working with its 194 Member States, WHO’s mission is to promote health, keep the world safe and serve the vulnerable. For more information about WHO, visit www.who.int. Follow WHO on Twitter and FacebookAbout Project EveryoneProject Everyone was co-founded by writer, director, and SDG Advocate Richard Curtis, Kate Garvey and Gail Gallie with the ambition to help achieve the Global Goals through raising awareness, holding leaders accountable, and driving action. Find out more at www.project-everyone.org.About Tiger Aspect ProductionsTiger Aspect Productions, part of Endemol Shine Group, is internationally recognised as one of the United Kingdom’s most successful and prolific independent television producers. Producing high profile, multi genre content for both United Kingdom and international audiences, current productions include Peaky Blinders (BBC One), Good Karma Hospital (ITV 1), Jack Whitehall: Travels with My Father (Netflix), Mr Bean (CITV), Hitmen (Sky One), Man Like Mobeen (BBC Three), and many more.
New tools to help ensure a positive pregnancy experience for women
on 22/06/2020 at 7:23 am
WHO provides practical steps to help countries adapt global guidance on antenatal care Governments can help to save lives and improve every woman’s and adolescent girl’s experience of pregnancy by updating their national guidelines with the WHO recommendations on antenatal care. For WHO recommendations to be effective however, they must be adapted to local context and monitored in a consistent way. That is why WHO has now released the Antenatal care recommendations adaptation toolkit, in collaboration with Ministries of Health, WHO Regional and Country offices, implementation experts and country stakeholders. The toolkit sets out practical steps for governments wishing to introduce WHO recommendations at national and subnational level. In addition, an antenatal care monitoring framework, has been developed to help countries and health facilities track their progress and impact. A standard process for adapting WHO guidance The WHO antenatal care guidelines for a positive pregnancy experience include 23 recommendations which are context-specific: they need tailoring to local situations, for example, populations with different nutritional needs or rates of infections. Currently there is no standardized method for implementing global recommendations at the national level. The new antenatal care toolkit guides policy makers in how to interpret and apply context-specific recommendations; steps which can be time-consuming but which are essential for providing care to meet each person’s needs and preferences. "Countries were not only asking for technical guidance on antenatal care, they also wanted an evidence-based approach on how to adapt that guidance for their own contexts,” explained Dr Nancy Kidula, a Medical Officer in the WHO Regional Office for Africa. Understanding local context to improve maternal health The Ugandan Ministry of Health has successfully used the new toolkit as part of efforts to improve women’s experience of care during pregnancy. Policy makers were able to take up the new recommendations while also addressing local practices which are not recommended, by following practical steps for community engagement, planning and analysis. They were also able to integrate antenatal care into the country’s wider maternal health framework, including TB screening and birth and emergency preparedness plans. "This new toolkit has galvanized country teams, changing the way that they look at antenatal care coverage, quality and availability, continued Dr Kidula, who supported the toolkit development and its implementation in Uganda, as well as eSwatini, Namibia, Rwanda and Zambia. “With the tools to analyse different levels of the health system, they have been able to see where there are not enough trained staff and essential supplies for the women seeking care. We are seeing a major difference in the antenatal care guideline of countries that have used the toolkit, and those that have not.” Monitoring delivery and impact of antenatal care Monitoring is an important part of the improvement process for routine antenatal care, at both country and health facility level. The new monitoring framework for the WHO antenatal care recommendations includes indicators on clinical care and strategies for improvement. Like the toolkit, the monitoring framework is meant for local adaptation, with global and context-specific indicators. It also identifies gaps where new indicators are needed: in particular, the lack of indicators currently available to capture an individual’s experience of care. This is crucial as experience of care is a core component of quality and respectful care, at the heart of the WHO recommendations on antenatal care for a positive pregnancy experience. Strategic support for countries to improve maternal health and beyond The new antenatal care toolkit is part of a wider strategy to improve support for countries adapting and implementing WHO guidelines across the maternity care continuum. “While the Ministry of Health has been proactively working towards strengthening the antenatal care in the country, there is need for aligning the package as per WHO recommendations,” explained Dr Ram Chahar, National Programme Officer (Maternal and Reproductive Health), WHO Country Office for India. “The use of the antenatal care toolkit has simplified the process of adaptation and revision of the existing antenatal care package.” A similar approach could be useful across all areas of health “When WHO guidelines are designed to be adapted for use in different contexts, they are more effective in addressing diverse health needs. As countries work to improve the health, well-being and rights of every individual, they need tools which can make WHO recommendations work, in turn, for them.” said Dr Ӧzge Tunçalp, a scientist at WHO/HRP. These tools and and other antenatal care resources will be available on the WHO Antenatal Care Portal, launching in July.
Countries failing to prevent violence against children, agencies warn
on 18/06/2020 at 8:31 pm
Half of the world’s children, or approximately 1 billion children each year are affected by physical, sexual or psychological violence, suffering injuries, disabilities and death, because countries have failed to follow established strategies to protect them. This is according to a new report published today by the World Health Organization (WHO), UNICEF, UNESCO, the Special Representative of the United Nations Secretary-General on Violence against Children and the End Violence Partnership. “There is never any excuse for violence against children," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “We have evidence-based tools to prevent it, which we urge all countries to implement. Protecting the health and well-being of children is central to protecting our collective health and well-being, now and for the future.”The report – Global Status Report on Preventing Violence Against Children 2020 – is the first of its kind, charting progress in 155 countries against the “INSPIRE” framework, a set of seven strategies for preventing and responding to violence against children. The report signals a clear need in all countries to scale up efforts to implement them. While nearly all countries (88%) have key laws in place to protect children against violence, less than half of countries (47%) said these were being strongly enforced. The report includes the first ever global homicide estimates specifically for children under 18 years of age – previous estimates were based on data that included 18 to 19-year olds. It finds that, in 2017, around 40,000 children were victims of homicide.“Violence against children has always been pervasive, and now things could be getting much worse,” said UNICEF Executive Director Henrietta Fore. “Lockdowns, school closures and movement restrictions have left far too many children stuck with their abusers, without the safe space that school would normally offer. It is urgent to scale up efforts to protect children during these times and beyond, including by designating social service workers as essential and strengthening child helplines.” Progress is generally unevenOf the INSPIRE strategies, only access to schools through enrollment showed the most progress with 54% of countries reporting that a sufficient number of children in need were being reached in this way. Between 32% to 37% of countries considered that victims of violence could access support services, while 26% of countries provided programmes on parent and caregiver support; 21% of countries had programmes to change harmful norms; and 15% of countries had modifications to provide safe physical environments for children. Although a majority of countries (83%) have national data on violence against children, only 21% used these to set baselines and national targets to prevent and respond to violence against children. About 80% of countries have national plans of action and policies but only one-fifth have plans that are fully funded or have measurable targets. A lack of funding combined with inadequate professional capacity are likely contributing factors and a reason why implementation has been slow. The COVID-19 response and its impact on children“During the COVID-19 pandemic, and the related school closures, we have seen a rise in violence and hate online – and this includes bullying. Now, as schools begin to re-open, children are expressing their fears about going back to school,” said Audrey Azoulay, UNESCO Director-General. “It is our collective responsibility to ensure that schools are safe environments for all children. We need to think and act collectively to stop violence at school and in our societies at large.”Stay-at-home measures including school closures have limited the usual sources of support for families and individuals such as friends, extended family or professionals. This further erodes victims’ ability to successfully cope with crises and the new routines of daily life. Spikes in calls to helplines for child abuse and intimate partner violence have been observed. And while online communities have become central to maintain many children’s learning, support and play, an increase in harmful online behaviours including cyberbullying, risky online behavior and sexual exploitation have been identified. “Whilst this report was being finalized, confinement measures and the disrupted provision of already limited child protection services exacerbated the vulnerability of children to various forms of violence,” said Najat Maalla M’jid, Special Representative of the United Nations Secretary-General on Violence against Children. “To respond to this crisis a unified, child rights and multisectoral framework for action for children is critical requiring a strong mobilization of governments, bilateral/multilateral donors, civil society, private sector and children, whose views must be heard and truly taken into account to ensure duly protection and the possibility for all to thrive and reach their full potential.”Accelerating action to protect childrenWHO and its partners will continue to work with countries to fully implement the INSPIRE strategies by enhancing coordination, developing and implementing national action plans, prioritizing data collection, and strengthening legislative frameworks. Global action is needed to ensure that the necessary financial and technical support is available to all countries. Monitoring and evaluation are crucial to determine the extent to which these prevention efforts are effectively delivered to all who need them.“Ending violence against children is the right thing to do, a smart investment to make, and it’s possible. It is time to fully fund comprehensive national action plans that will keep children safe at home, at school, online and in their communities,” said Dr Howard Taylor, End Violence Partnership. “We can and must create a world where every child can thrive free from violence and become a new generation of adults to experience healthy and prosperous lives.” Editor’s note:The data for the report was compiled through a survey administered between 2018 and 2019 with responses from over 1000 decision-makers from 155 countries. The INSPIRE strategies launched in 2016 call for the implementation and enforcement of laws; changing norms and values to make violence unacceptable; creating safe physical environments for children; providing support to parent and caregivers; strengthening income and economic security and stability; improving response and support services for victims; and providing children with education and life skills.Related linksTo download the report (in English only) and executive summary (in English, French, Russian and Spanish), go to: https://who.canto.global/b/SSHOR and use password: 490759.To watch the launch event taking place on Thursday, 18 June from 15:00 to 16:30 CEST, please register at https://bit.ly/2ApZXKa. After registering, you will receive a confirmation email with details on how to access the event. Interpretation will be provided in the 6 UN languages.The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with 194 Member States, across six regions and from more than 150 offices, to promote health, keep the world safe and serve the vulnerable. Our goal for 2019-2023 is to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and provide a further billion people with better health and wellbeing. For more information about WHO, visit www.who.int. Follow WHO on Twitter and Facebook.UNICEF works in some of the world’s toughest places, to reach the world’s most disadvantaged children. Across more than 190 countries and territories, we work for every child, everywhere, to build a better world for everyone. For more information about UNICEF and its work for children, visit www.unicef.org. Follow UNICEF on Twitter and Facebook.The Special Representative of the United Nations Secretary-General on Violence against Children is a global independent advocate promoting the prevention and elimination of all forms of violence against children. The Special Representative acts as a bridge builder and a catalyst of actions in all regions, across sectors and settings where violence against children may occur. She mobilizes political support to generate renewed concern at the harmful effects of violence on children working with Governments, national institutions, civil society organizations and children promoting behavioral and social change to end violence against children by 2030. For more Information, visit: https://violenceagainstchildren.un.org/. Follow on Twitter Facebook and InstagramThe End Violence Partnership is a public-private partnership established by the UN Secretary-General in 2016. End Violence is made up of over 420 partners and act as a global platform for advocacy, evidence-based action and investments to end all forms of violence against children. The End Violence Partnership focus on three main areas: keeping children safe at home, online and in and through schools.UNESCO is the United Nations Educational, Scientific and Cultural Organisation. It seeks to build peace through international co-operation in Education, the Sciences and Culture. UNESCO's programmes contribute to the Sustainable Development defined in Agenda 2030, adopted by the UN General Assembly in 2015.
WHO welcomes FDA approval of new formulation of dolutegravir for young children living with HIV
on 18/06/2020 at 4:24 pm
WHO welcomes the recent decision by the U.S. Food and Drug Administration (FDA) to approve a dispersible 5 mg formulation of dolutegravir (DTG) for use in infants and children living with human immunodeficiency virus type 1 (HIV-1). The tablet, taken orally, has been approved for use in paediatric patients from four weeks of age weighing at least 3 kg in combination with other antiretroviral treatments.
Call for expression of interest: Data gathering and analysis on electricity access in healthcare facilities
on 18/06/2020 at 1:43 pm
The purpose of this full-time consultancy is to take stock and analyse existing data with regards to electricity access in healthcare facilities in low-income countries, and through this activity also contribute to the preparation of a ‘Global Assessment of Electricity in Healthcare Facilities’ report. The consultant will support the health and energy team within the Air Quality and Health (AQH) Unit of the WHO’s Department of Environment, Climate Change, and Health. The activity is part of WHO's work as Secretariat of the Global Health and Energy Platform of Action.
Call for expression of interest: Global assessment of electricity in healthcare facilities report
on 18/06/2020 at 1:23 pm
The purpose of this consultancy is to support WHO and partners on the development of the 'Global Assessment of Electricity in Healthcare Facilities’ report. The consultancy entity will support the health and energy team within the Air Quality and Health (AQH) Unit of the WHO’s Department of Environment, Climate Change, and Health.
Luxembourg and WHO sign new Memorandum of Understanding, committing flexible funding to support WHO Triple billion targets
on 18/06/2020 at 12:20 pm
Today Luxembourg’s Minister for Development Cooperation and Humanitarian Affairs and Minister of the Economy, Mr Franz Fayot, and WHO Director General Dr Tedros Adhanom Ghebreyesus signed a new Memorandum of Understanding (MoU) for the period 2020-2023 in support of the Organization’s Thirteenth General Programme of work 2019-2023. The signature of the new MOU underscores the longstanding commitment of the Government of the Grand Duchy of Luxembourg – an important partner in global health – to help WHO to achieve its ambitious triple billion targets by 2023: 1 billion more people will benefit from universal health coverage; 1 billion more will be better protected in health emergencies, and 1 billion more will enjoy improved health and wellbeing. “The partnership with Luxembourg is very special to WHO and we are extremely grateful for the multi-annual, flexible funding Luxembourg provides,” said Dr Tedros. The overall objective of the MoU is to support the achievement of the Sustainable Development Goals through WHO’s work in countries, focussing on three broad areas: Achieving universal health coverage Addressing health emergencies Promoting healthier populations By providing flexible and predictable funding to WHO, Luxembourg is effectively helping WHO to be agile and strategic in achieving its triple billion goals. The new MoU also addresses gender equality in line with the UN System-wide Action Plan on Gender Equality and the Empowerment of Women, that enables gender issues to be mainstreamed systematically and measurably into all UN functions and entities, and highlights the importance of the Junior Professional Officer programme. The signature of the new MoU follows Luxembourg’s support to WHO in March 2020 for the COVID-19 response, to the WHO Contingency Fund for Emergencies and the COVID-19 Technology Access Pool (C-TAP), an initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all. Read more about how WHO and Luxembourg are working together to improve the health and well-being of all people, of all ages. Investing in a healthier world: Read about how other countries are partnering with WHO.
WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients
on 16/06/2020 at 9:15 pm
The World Health Organization (WHO) welcomes the initial clinical trial results from the United Kingdom (United Kingdom) that show dexamethasone, a corticosteroid, can be lifesaving for patients who are critically ill with COVID-19. For patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth, according to preliminary findings shared with WHO.The benefit was only seen in patients seriously ill with COVID-19, and was not observed in patients with milder disease. “This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This is great news and I congratulate the Government of the United Kingdom, the University of Oxford, and the many hospitals and patients in the United Kingdom who have contributed to this lifesaving scientific breakthrough.”Dexamethasone is a steroid that has been used since the 1960s to reduce inflammation in a range of conditions, including inflammatory disorders and certain cancers. It has been listed on the WHO Model List of Essential Medicines since 1977 in multiple formulations, and is currently off-patent and affordably available in most countries.The researchers shared initial insights about the results of the trial with WHO, and we are looking forward to the full data analysis in the coming days. WHO will coordinate a meta-analysis to increase our overall understanding of this intervention. WHO clinical guidance will be updated to reflect how and when the drug should be used in COVID-19.Today’s news builds off the WHO Research & Development Blueprint meeting, which took place in Geneva in mid-February to accelerate health technologies for COVID-19, where further research into the use of steroids was highlighted as a priority. The findings reinforce the importance of large randomized control trials that produce actionable evidence. WHO will continue to work together with all partners to further develop lifesaving therapeutics and vaccines to tackle COVID-19 including under the umbrella of the Access to COVID-19 Tools Accelerator.